Health News

Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara((R)) (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive).

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Drug, medicine, Pharmacy, Surgery

Related posts

• Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study (0)
  The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis. Read more [tags] Pharmacy News [/tags]
  
  
• Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports (0)
  A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa(R) (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone(1). Read more [tags] Pharmacy News [/tags]
  
  
• Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer (0)
  Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin. Read more [tags] Pharmacy News [/tags]
  
  
• Positive Phase II Results With Iniparib (BSI-201) In Women With Metastatic Triple Negative Breast Cancer (0)
  Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine (NEJM) published the final phase II data for the investigational drug iniparib* (BSI-201) demonstrating significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when iniparib was administered in... Read more [tags] Pharmacy News [...]
  
  
• PINC trial to test anti-malarial drug in women with DCIS (0)
  Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove. Read more [tags] Pharmacy News [/tags]